Compare NREF & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | SABS |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.0M | 293.9M |
| IPO Year | N/A | 2020 |
| Metric | NREF | SABS |
|---|---|---|
| Price | $12.17 | $3.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $14.50 | $11.64 |
| AVG Volume (30 Days) | 60.2K | ★ 672.8K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 15.79% | N/A |
| EPS Growth | N/A | ★ 78.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $4.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.60 | $2.44 |
| 52 Week High | $18.43 | $5.15 |
| Indicator | NREF | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 24.86 | 48.54 |
| Support Level | N/A | $2.44 |
| Resistance Level | $16.04 | $4.03 |
| Average True Range (ATR) | 0.63 | 0.23 |
| MACD | -0.22 | 0.01 |
| Stochastic Oscillator | 2.51 | 38.33 |
NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.